Lexicon Pharmaceuticals Inc. provided a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference. The company reported that enrollment for the SONATA-HCM trial is expected to be completed in 2026, with topline data anticipated in 2027. Lexicon triggered a $10 million milestone payment from a licensing agreement with Novo Nordisk for LX9851. The company also stated that Zynquista is on track for NDA resubmission and potential approval in 2026. Additional updates included progress on pilavapadin for neuropathic pain, following a productive End-of-Phase 2 meeting with the FDA in late 2025, and ongoing partnership discussions to advance the therapy globally. Lexicon also highlighted international expansion of the sotagliflozin program through Viatris, with regulatory approval received in the United Arab Emirates and applications submitted in Canada, Australia, and New Zealand in 2025. Further regulatory submissions and approvals are expected in key markets throughout 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623751) on January 12, 2026, and is solely responsible for the information contained therein.
Comments